Oncotarget

Case Reports:

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

Johnny Boustany _, Maher Abdessater, Charbel El Hachem, Ziad El Khoury, Walid El Khoury and Raghid El Khoury

PDF  |  Full Text  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2020; 11:1922-1928. https://doi.org/10.18632/oncotarget.27543

Metrics: PDF 149 views  |   Full Text 309 views  |   ?  


Abstract

Johnny Boustany1,2, Maher Abdessater1,2, Charbel El Hachem1,2, Ziad El Khoury1,2, Walid El Khoury1,2 and Raghid El Khoury1,2

1 Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon

2 Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon

Correspondence to:

Johnny Boustany,email: johnnyboustany@live.com

Keywords: clear cell renal carcinoma; sarcomatoid dedifferentiation; metastasectomy; cabozantinib

Received: December 09, 2019     Accepted: March 14, 2020     Published: May 19, 2020

ABSTRACT

Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy.

The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib.

Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life.

Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27543